Results 121 to 130 of about 87,264 (316)

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

ESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti, Javed Butler, Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Johann Bauersachs, Antoni Bayes‐Genis, Shaun G. Goodman, Tomasz Gasior, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker   +23 more
wiley   +1 more source

Cardiomyopathy prediction in patients with permanent ventricular pacing using machine learning methods

Sistemnì Doslìdženâ ta Informacìjnì Tehnologìï
Pacing-induced cardiomyopathy is a notable issue in patients needing permanent ventricular pacing. Identifying risk groups early and swiftly preventing the ailment can reduce patient harm. However, current prognostic methods require clarity. We employed
Eugene Perepeka, Vasyl Lazoryshynets, Vitalii Babenko, Illia Davydovych, Ievgen Nastenko   +4 more
doaj   +1 more source

Pacing-Induced Ventricular Remodeling in the Chick Embryonic Heart [PDF]

, 1999
David Sedmera, M Grobéty, Christophe Reymond, P Baehler, Pavel Kučera, Lukas Kappenberger   +5 more
openalex   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

ESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz, Francesco Fioretti, Sara Ladak, Mohammed Obaidan, Javed Butler, Aamir Hameed   +5 more
wiley   +1 more source

Characterization of health care utilization in patients receiving implantable cardioverter-defibrillator therapies: An analysis of the managed ventricular pacing trial. [PDF]

, 2017
BACKGROUND: Implantable cardioverter-defibrillators (ICDs) are effective in terminating lethal arrhythmias, but little is known about the degree of health care utilization (HCU) after ICD therapies.
Cheng, Alan, Ellenbogen, Kenneth A., Nahey, Tara, Peterson, Brett J., Rickard, John, Sherfesee, Lou, Tang, Anthony S., Whellan, David J.   +7 more
core   +1 more source

302 Impact of right ventricular pacing in patients with TAVI underwent permanent pacemaker implantation: the Pace-TAVI International Multicentre Study [PDF]

, 2021
Francesco Bruno, Fabrizio D ́ascenzo, Isabel Muñoz‐Pousa, Francesco Saia, Matteo Pio Vaira, Enrico Baldi, Pier Pasquale Leone, Pilar Cabanas‐Grandío, Nicola Corcione, Enrico Guido Spinoni, Gianmarco Annibali, Caterina Russo, Matteo Ziacchi, C Caruzzo, Marco Ferlini, Giuseppe Lanzillo, Ovidio De Filippo, Guglielmo Gallone, Davide Castagno, Giuseppe Patti, Giuseppe Musumeci, Arturo Giordano, Giulio Stefanini, Stefano Salizzoni, Roberto Rordorf, Emad Abu Essi, Sergio Raposeiras Rubin, Mauro Biffi, Federico De Marco, Gaetano Maria De Ferrari   +29 more
openalex   +1 more source

Takotsubo cardiomyopathy during armed conflict: A case series

ESC Heart Failure, Volume 12, Issue 2, Page 1494-1498, April 2025.
Sharon Bruoha, Artyom Star, Gili Givaty, Michael Shilo, Michael Friger, Vladimir Chitoroga, Hezzy Shmueli, Yigal Abramowitz, Elad Asher, Jamal Jafari, Vladimir Shlyakhover, Doron Zahger, Moti Haim, Chaim Yosefy   +13 more
wiley   +1 more source

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

ESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori, Sergio Davinelli, Armando Ferrera, Alessandro Medoro, Carlo Barsali, Allegra Battistoni, Maurizio Volterrani, Massimo Volpe, Luciano Saso, Speranza Rubattu   +9 more
wiley   +1 more source

Meta‐analysis of biventricular vs. right ventricular pacing mode in patients with atrial fibrillation undergoing atrioventricular nodal ablation: what was the quality of the included trials? ‐ reply [PDF]

, 2012
Neal A. Chatterjee, Gaurav A. Upadhyay, Jagmeet P. Singh   +2 more
openalex   +1 more source

First evaluation of a novel pulsatile LVAD: Feasibility and haemodynamic impact in acute heart failure

ESC Heart Failure, EarlyView.
The pulsatile ventricular assist platform (pVAP) was connected to a membrane pump in six large swine models. The system, driven by a conventional intra‐aortic balloon pump console (IABP), was utilized to drain left atrial blood during systole and to eject the collected blood back into the ascending aorta during diastole.
Sara Knigge, Marcelo B. Bastos, Bastian Schmack, Liam Schana, Oren Malchin, Ali S. Merzah, Aron F. Popov, Alexander Weymann, Arjang Ruhparwar, Felix Schumacher, Günes Dogan, Jan D. Schmitto   +11 more
wiley   +1 more source